Axel Grothey, MD

Axel Grothey, MD, medical oncologist at West Cancer Center, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib (Braftovi), MEK inhibitor binimetinib (Mektovi), and anti-EGFR antibody cetuximab (Erbitux) in patients with

V600E-mutant metastatic colorectal cancer (mCRC).

Out of the 30 patients available for the safety analysis, 29 were available for efficacy. There was a response rate of 48% among these patients. Also, not one patient had progression of disease by RECIST criteria in this analysis.

The median progression-free survival is 8 months in this patient population, which far exceeds historical controls of about 2 to 4 months. Additionally, the median overall survival is 15.3 months, which is almost 3 times as long as current standards of care. Grothey notes that this is much longer than seen with other biologic combinations in this setting.

See more from the 2019 Gastrointestinal Cancers Symposium.

Videos

Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in&nbsp;patients with&nbsp;<em>BRAF</em>V600E-mutant metastatic colorectal cancer.

Grothey Shares Encouraging Data from Lead-In Phase of BEACON CRC Trial 

Axel Grothey, MD, medical oncologist, Department of Oncology, Mayo Clinic, discusses the role of sidedness in tumor location in colorectal cancer.

The Role of Sidedness in Colorectal Cancer

Axel Grothey, MD, Mayo Clinic in Rochester, Minnesota, discusses the Lume 1 and 2 trials as well as new treatment options for metastatic colorectal cancer.

Overview of the Lume 1 and 2 Trials

Articles

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.

Axel Grothey, MD | Authors

Articles

Grothey Shares Encouraging Data from Lead-In Phase of BEACON CRC Trial

The Role of Sidedness in Colorectal Cancer

Overview of the Lume 1 and 2 Trials

Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials